Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
With our SWIDINEP cohort, we propose to explore the relationship between vascular risk markers and renal function decline in CKD stage 1-5. In order to realize these goals, we intend to recruit 200 patients within a 7y recruitment period (2014-2021). Recruitment is done in the nephrology and diabetes ambulatory clinics in the CHUV at Lausanne. Each eligible patient is identified and whether he/she can be proposed the study is discussed with the physician in charge of the patient. Once the patient is informed and has signed the consent form, he/she is examined in the Service of Nephrology at baseline, 2y and 5y.
Serum, plasma, and fresh urine samples as well as whole blood (buffy coat for DNA extraction and genotyping) are stored at -80°C in a local biobank according to the latest guidelines of the Académie Suisse des Sciences Médicales (ASSM).
The vascular phenotype includes:
Quality of life questionnaires: A number of studies have shown that as kidney function decreases, disease burden increases, with lower health-related quality of life (HRQoL) for patients with late stages of chronic kidney disease. However, few studies have looked into HRQoL and its determinants in the specific population of diabetic patients with kidney disease. Assessing HRQoL and its determinants is important in chronic care as studies have shown that patients with higher HRQoL function better within the healthcare system and perform more health-promoting activities. HRQoL is assessed at baseline in patients enrolled in the cohort. The impact of baseline HRQoL on renal function decline will be analysed.
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Measure | Description | Time Frame |
|---|---|---|
| estimated GFR decline ml/min/y | estimated GFR will be based on the creatinine based CKD-EPI formula | 2-5 years |
| Measure | Description | Time Frame |
|---|---|---|
| 24 hour blood pressure measurements (mmHg) and eGFR decline (ml/min/y) | Relationship of 24h blood pressure diurnal pattern and eGFR decline | 2-5 years |
| Vascular markers (Pulse wave velocity (m/s); Carotid and radial augmentation indexes (%); intima media thickness (mm)) and eGFR decline (ml/min/y) |
Not provided
Inclusion Criteria:
Exclusion Criteria:
Not provided
Not provided
Not provided
Individuals with type 2 diabetes and CKD stage 1-5
Not provided
Not provided
| Facility | Status | City | State | ZIP | Country | Contacts |
|---|---|---|---|---|---|---|
| Centre Hospitalier Universitaire Vaudois | Lausanne | Canton of Vaud | 1011 | Switzerland |
Not provided
| ID | Term |
|---|---|
| D003928 | Diabetic Nephropathies |
| ID | Term |
|---|---|
| D007674 | Kidney Diseases |
| D014570 | Urologic Diseases |
| D052776 | Female Urogenital Diseases |
| D005261 | Female Urogenital Diseases and Pregnancy Complications |
Not provided
Not provided
Not provided
Not provided
Not provided
Serum, plasma, and fresh urine samples as well as whole blood (buffy coat for DNA extraction and genotyping) are stored at -80°C in a local biobank according to the latest guidelines of the Académie Suisse des Sciences Médicales (ASSM).
Relationship of baseline vascular markers and eGFR decline |
| 2-5 years |
| Kidney volume (cm3) and resistance index and eGFR decline (ml/min/y) | Relationship of renal volume/resistance index and eGFR decline | 2-5y |
| Biochemical parameters and eGFR decline (ml/min/y) | Relationship of baseline biochemical biomarkers and eGFR decline | 2-5y |
| Genetic markers and eGFR decline (ml/min/y) | Relationship of genetic markers and eGFR decline | 2-5y |
| Choroidal thickness (microm) and eGFR decline (ml/min/y) | Relationship of baseline choroidal thickness and eGFR decline | 2-5y |
| Generic health-related quality of life baseline measures, CKD stage, and eGFR decline. | The influence of CKD stage and eGFR decline on generic and diabetes-specific health related quality of life questionnaires. | 2-5y |
| Diabetes-specific health-related quality of life baseline measures, CKD stage, and eGFR decline. | The influence of CKD stage and eGFR decline on generic and diabetes-specific health related quality of life questionnaires. | 2-5y |
| D000091642 | Urogenital Diseases |
| D052801 | Male Urogenital Diseases |
| D048909 | Diabetes Complications |
| D003920 | Diabetes Mellitus |
| D004700 | Endocrine System Diseases |